Drug intelligence / Profile preview

chlorphenamine + phenylephrine + paracetamol

Development stage
Phase 3
Lead developer
Biofarma
Modality
Small Molecules
Administration
Oral
01

Overview

Gerakon Forte is a branded generic oral combination medication developed and marketed by Biofarma for the symptomatic relief of common cold, flu, and upper respiratory tract infections. It is formulated as an immediate-release tablet containing three active ingredients: paracetamol (650 mg), an analgesic and antipyretic that reduces pain and fever; phenylephrine hydrochloride (10 mg), a decongestant that relieves nasal stuffiness by constricting blood vessels; and chlorpheniramine maleate (4 mg), a first-generation antihistamine that alleviates allergic symptoms such as runny nose, sneezing, and watery eyes. Together, these components target multiple pathways to manage the systemic and localized symptoms of respiratory illnesses.

Brand names
Gerakon FortGerakon Forte
Other names
acetaminophen + chlorphenamine + phenylephrineacetaminophen + chlorpheniramine + phenylephrinechlorphenamine + phenylephrine + paracetamolchlorphenamine maleate + phenylephrine hydrochloride + paracetamolchlorpheniramine + phenylephrine + paracetamolchlorpheniramine maleate + phenylephrine hydrochloride + paracetamol
02

Targets

ADRA1A (α1A)HRH1 (Histamine H1 Receptor)SERT (Sodium-dependent serotonin transporter)ADRA1B (α1B)ADRA1D (α1D)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on chlorphenamine + phenylephrine + paracetamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on chlorphenamine + phenylephrine + paracetamol.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call